BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 30368665)

  • 21. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
    Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
    BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma.
    Saeednejad Zanjani L; Madjd Z; Abolhasani M; Andersson Y; Rasti A; Shariftabrizi A; Asgari M
    Exp Mol Pathol; 2017 Oct; 103(2):218-228. PubMed ID: 29050853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
    Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
    BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma.
    Haddad AQ; Kapur P; Singla N; Raman JD; Then MT; Nuhn P; Buchner A; Bastian P; Seitz C; Shariat SF; Bensalah K; Rioux-Leclercq N; Sagalowsky A; Lotan Y; Margulis V
    Cancer; 2015 Jan; 121(1):43-50. PubMed ID: 25186283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease.
    Campbell L; Al-Jayyoussi G; Gutteridge R; Gumbleton N; Griffiths R; Gumbleton S; Smith MW; Griffiths DF; Gumbleton M
    J Transl Med; 2013 Oct; 11():255. PubMed ID: 24119769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas.
    Chaux A; Albadine R; Schultz L; Hicks J; Carducci MA; Argani P; Allaf M; Netto GJ
    Hum Pathol; 2013 Oct; 44(10):2323-30. PubMed ID: 23953228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma.
    Bui MH; Visapaa H; Seligson D; Kim H; Han KR; Huang Y; Horvath S; Stanbridge EJ; Palotie A; Figlin RA; Belldegrun AS
    J Urol; 2004 Jun; 171(6 Pt 1):2461-6. PubMed ID: 15126876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer.
    Mizuno T; Kamai T; Abe H; Sakamoto S; Kitajima K; Nishihara D; Yuki H; Kambara T; Betsunoh H; Yashi M; Fukabori Y; Kaji Y; Yoshida K
    BMC Cancer; 2015; 15():1097. PubMed ID: 25784113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel prognostic model for patients with sarcomatoid renal cell carcinoma.
    Zhang BY; Thompson RH; Lohse CM; Leibovich BC; Boorjian SA; Cheville JC; Costello BA
    BJU Int; 2015 Mar; 115(3):405-11. PubMed ID: 24730416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases.
    Maas M; Kurcz A; Hennenlotter J; Scharpf M; Fend F; Walz S; Stühler V; Todenhöfer T; Stenzl A; Bedke J; Rausch S
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low NR3C2 levels correlate with aggressive features and poor prognosis in non-distant metastatic clear-cell renal cell carcinoma.
    Zhao Z; Zhang M; Duan X; Deng T; Qiu H; Zeng G
    J Cell Physiol; 2018 Oct; 233(10):6825-6838. PubMed ID: 29693713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.
    Sellin JN; Reichardt W; Bishop AJ; Suki D; Rhines LD; Settle SH; Brown PD; Li J; Rao G; Chang EL; Tatsui CE
    J Neurosurg Spine; 2015 Jan; 22(1):52-9. PubMed ID: 25360530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased expression of Chitinase 3-like 1 and microvessel density predicts metastasis and poor prognosis in clear cell renal cell carcinoma.
    Zhang JP; Yuan HX; Kong WT; Liu Y; Lin ZM; Wangs WP; Guo JM
    Tumour Biol; 2014 Dec; 35(12):12131-7. PubMed ID: 25142236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.
    Bodnar L; Stec R; Cierniak S; Synowiec A; Wcisło G; Jesiotr M; Koktysz R; Kozłowski W; Szczylik C
    Ann Oncol; 2015 Jul; 26(7):1385-9. PubMed ID: 25962440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
    Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
    BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker.
    Knoll M; Macher-Goeppinger S; Kopitz J; Duensing S; Pahernik S; Hohenfellner M; Schirmacher P; Roth W
    Oncotarget; 2016 Jan; 7(1):418-32. PubMed ID: 26506236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma.
    Zhang X; Yin X; Zhang H; Sun G; Yang Y; Chen J; Shu K; Zhao J; Zhao P; Chen N; Wang J; Shen P; Zeng H
    BMC Cancer; 2019 Jan; 19(1):49. PubMed ID: 30630458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
    Terakawa T; Miyake H; Kusuda Y; Fujisawa M
    Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels.
    Horstmann M; Merseburger AS; von der Heyde E; Serth J; Wegener G; Mengel M; Feil G; Hennenlotter J; Nagele U; Anastasiadis A; Bokemeyer C; Stenzl A; Kuczyk M
    J Cancer Res Clin Oncol; 2005 Nov; 131(11):715-22. PubMed ID: 16080018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.